Australia: Preferred Destination for Early Phase Clinical Trials

Published: 12 Sep 2016

Executive Summary

WHAT

The clinical trials process is complex. It requires substantial investment and skilled human re-sources, and involves risks, not least, the navigation of complex regulatory processes. To over-come these challenges, small biotechnology companies outsource their early phase clinical studies to contract research organizations (CROs). This white paper highlights research on why Australia continues to be a hub for early phase clinical trials.

WHY

Reasons to outsource to Australia vary by country. Fast approval times with lower costs and comparable quality appeal to US companies. Chinese companies seek faster and more transparent approval processes, with results that will be acceptable to the US Food and Drug Administration (US FDA). There are 3 key benefits in outsourcing early phase clinical trials to Australia:

Sign in to read the rest of this article

Not signed up? Register now Forgot your password?

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..